BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma
Open Access
- 1 March 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (5) , 1623-1629
Abstract
Purpose: Oncogenic conversion of BRAF occurs in ∼44% of papillary thyroid carcinomas and 24% of anaplastic thyroid carcinomas. In papillary thyroid carcinomas, this mutation is associated with an unfavorable clinicopathologic outcome. Our aim was to exploit BRAF as a potential therapeutic target for thyroid carcinoma.Keywords
This publication has 34 references indexed in Scilit:
- Playing dirtyNature, 2005
- Raf: A Strategic Target for Therapeutic Development Against CancerJournal of Clinical Oncology, 2005
- BRAF mutation in thyroid cancerEndocrine-Related Cancer, 2005
- Targeting the mitogen-activated protein kinase cascade to treat cancerNature Reviews Cancer, 2004
- Targeted cancer therapyNature, 2004
- Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAsNature, 2004
- B-RAF is a therapeutic target in melanomaOncogene, 2004
- Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAFCell, 2004
- Cytokine Production by a New Undifferentiated Human Thyroid Carcinoma Cell Line, FB-1The Journal of Clinical Endocrinology & Metabolism, 1997
- Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.Journal of Cell Biology, 1992